Rating Change
Chardan Capital analysts initiated coverage on Gossamer Bio, Inc. (NASDAQ:GOSS) with a rating of Buy on October 13, 2026.
new coverageNASDAQ:GOSS
Chardan Capital Initiates Coverage on Gossamer Bio, Inc. (GOSS) with Buy
Chardan Capital analysts initiated coverage on Gossamer Bio, Inc. (NASDAQ:GOSS) with a rating of Buy on October 13, 2026.
At publication ·
What changed
Gossamer Bio, Inc. (NASDAQ:GOSS) · new coverage
- Firm
- Chardan Capital
- Rating
- Buy
- Price at event
- $9.76
- Market capitalization
- $824.3M
At a glance
Key takeaways
- Chardan Capital initiated Buy coverage on Gossamer Bio (GOSS) trading at $9.76 with $824.3M market cap on October 13, 2026.
- The stock has surged 262.5% over the past 52 weeks, significantly outperforming broader market trends.
Market Context
Gossamer Bio, Inc. operates in the Healthcare sector. The stock currently trades at $9.76 with a market capitalization of $824.3M. The stock has gained 262.5% over the past 52 weeks.
Analyst coverage from Chardan Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Gossamer Bio, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Gossamer Bio, Inc.
Among the 10 most recent ratings: 8 Buy, 1 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 13, 2026 | Chardan Capital | Buy | N/A |
| Sep 21, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 14, 2026 | Piper Sandler | Overweight | N/A |
| Jul 28, 2026 | Leerink Partners | Outperform | N/A |
| Jul 27, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View GOSS Stock Page
Frequently Asked Questions
What does the Buy rating mean for GOSS?
A rating of Buy from Chardan Capital reflects the analyst's outlook on Gossamer Bio, Inc. (NASDAQ:GOSS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the GOSS forecast page.